Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors.

Yin A, Moes DJAR, van Hasselt JGC, Swen JJ, Guchelaar HJ.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 28. doi: 10.1002/psp4.12450. [Epub ahead of print] Review.

2.

A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.

Bank PCD, Swen JJ, Schaap RD, Klootwijk DB, Baak-Pablo R, Guchelaar HJ.

Eur J Hum Genet. 2019 Jun 21. doi: 10.1038/s41431-019-0454-x. [Epub ahead of print]

PMID:
31227807
3.

Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al.

Guchelaar HJ, Sanchez-Spitman A, Dezentjé V, Böhringer S, Swen J, Neven P, Gelderblom H.

J Clin Oncol. 2019 Jun 18:JCO1900932. doi: 10.1200/JCO.19.00932. [Epub ahead of print] No abstract available.

PMID:
31211601
4.
5.

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.

van der Wouden CH, Bank PCD, Özokcu K, Swen JJ, Guchelaar HJ.

Genes (Basel). 2019 May 29;10(6). pii: E416. doi: 10.3390/genes10060416.

6.

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.

van der Stoep MYEC, Zwaveling J, Bertaina A, Locatelli F, Guchelaar HJ, Lankester AC, Moes DJAR.

Br J Clin Pharmacol. 2019 May 29. doi: 10.1111/bcp.13995. [Epub ahead of print]

PMID:
31144349
7.

Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.

van der Wouden CH, van Rhenen MH, Jama WOM, Ingelman-Sundberg M, Lauschke VM, Konta L, Schwab M, Swen JJ, Guchelaar HJ.

Clin Pharmacol Ther. 2019 Apr 30. doi: 10.1002/cpt.1489. [Epub ahead of print]

PMID:
31038729
8.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

9.

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.

Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ.

Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536. doi: 10.1080/17512433.2019.1610390. Epub 2019 Apr 30. Review.

PMID:
31008668
10.

Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma.

Au L, Koudijs KKM, Terwisscha van Scheltinga AGT, Guchelaar HJ.

Cancer J. 2019 Mar/Apr;25(2):147-148. doi: 10.1097/PPO.0000000000000364. No abstract available.

PMID:
30896538
11.

Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology.

Koudijs KKM, Terwisscha van Scheltinga AGT, Böhringer S, Schimmel KJM, Guchelaar HJ.

Cancer J. 2019 Mar/Apr;25(2):116-120. doi: 10.1097/PPO.0000000000000370.

PMID:
30896533
12.

The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples.

Koudijs KKM, Terwisscha van Scheltinga AGT, Böhringer S, Schimmel KJM, Guchelaar HJ.

Sci Rep. 2019 Feb 21;9(1):2495. doi: 10.1038/s41598-019-39891-y.

13.

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.

Verboom MC, Kloth JSL, Swen JJ, Sleijfer S, Reyners AKL, Steeghs N, Mathijssen RHJ, Gelderblom H, Guchelaar HJ.

Pharmacogenomics J. 2019 Feb 4. doi: 10.1038/s41397-019-0079-z. [Epub ahead of print]

PMID:
30713339
14.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.

Henricks LM, Lunenburg CATC, Cats A, Mathijssen RHJ, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2019 Feb;20(2):e67. doi: 10.1016/S1470-2045(19)30010-5. No abstract available.

PMID:
30712800
15.

Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.

Sluiter RL, van Marrewijk C, de Jong D, Scheffer H, Guchelaar HJ, Derijks L, Wong DR, Hooymans P, Vermeulen SH, Verbeek ALM, Franke B, van der Wilt GJ, Kievit W, Coenen MJH.

J Crohns Colitis. 2019 Jan 30. doi: 10.1093/ecco-jcc/jjz009. [Epub ahead of print]

PMID:
30698675
16.

Adverse drug reactions on sexual functioning: a systematic overview.

Gordijn R, Teichert M, Nicolai MPJ, Elzevier HW, Guchelaar HJ.

Drug Discov Today. 2019 Mar;24(3):890-897. doi: 10.1016/j.drudis.2019.01.012. Epub 2019 Jan 25. Review.

PMID:
30690197
17.

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.

Sanchez-Spitman A, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ.

J Clin Oncol. 2019 Mar 10;37(8):636-646. doi: 10.1200/JCO.18.00307. Epub 2019 Jan 24.

PMID:
30676859
18.

Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.

Eektimmerman F, Allaart CF, Hazes JM, den Broeder AA, Fransen J, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2019 Jan;20(2):85-93. doi: 10.2217/pgs-2018-0144. Epub 2019 Jan 10.

PMID:
30628539
19.

Confirmation practice in pharmacogenetic testing; how good is good enough?

Lunenburg CATC, Guchelaar HJ, van Schaik RHN, Neumaier M, Swen JJ.

Clin Chim Acta. 2019 Mar;490:77-80. doi: 10.1016/j.cca.2018.12.023. Epub 2018 Dec 21.

PMID:
30582901
20.

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.

Baas J, Krens L, Bohringer S, Mol L, Punt C, Guchelaar HJ, Gelderblom H.

PLoS One. 2018 Dec 17;13(12):e0208080. doi: 10.1371/journal.pone.0208080. eCollection 2018.

21.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
22.

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants.

Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Mathijssen RHJ, Schellens JHM, Gelderblom H, Guchelaar HJ, Swen JJ.

Genes (Basel). 2018 Nov 28;9(12). pii: E585. doi: 10.3390/genes9120585.

23.

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, Toffoli G, Guchelaar HJ, Swen JJ, Cecchin E, Schellens JHM, Gelderblom H.

Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.

PMID:
30361102
24.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
25.

Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.

Zwart TC, Gokoel SRM, van der Boog PJM, de Fijter JW, Kweekel DM, Swen JJ, Guchelaar HJ, Moes DJAR.

Br J Clin Pharmacol. 2018 Dec;84(12):2889-2902. doi: 10.1111/bcp.13755. Epub 2018 Oct 15.

PMID:
30176064
26.

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.

Sanchez-Spitman AB, Dezentjé VO, Swen JJ, Moes DJAR, Gelderblom H, Guchelaar HJ.

Breast Cancer Res Treat. 2018 Nov;172(2):401-411. doi: 10.1007/s10549-018-4923-7. Epub 2018 Aug 17.

27.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

28.

Pharmacogenomics, a novel section in the European Journal of Human Genetics.

Guchelaar HJ.

Eur J Hum Genet. 2018 Oct;26(10):1399-1400. doi: 10.1038/s41431-018-0205-4. Epub 2018 Jul 2. No abstract available.

PMID:
29967335
29.

Implementation of Pharmacogenomics in Everyday Clinical Settings.

Bank PCD, Swen JJ, Guchelaar HJ.

Adv Pharmacol. 2018;83:219-246. doi: 10.1016/bs.apha.2018.04.003.

PMID:
29801576
30.

The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review.

van Beusekom MM, Kerkhoven AH, Bos MJW, Guchelaar HJ, van den Broek JM.

Drug Discov Today. 2018 Jun;23(6):1312-1318. doi: 10.1016/j.drudis.2018.05.013. Epub 2018 May 7. Review.

31.

A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.

Coppens DGM, de Wilde S, Guchelaar HJ, De Bruin ML, Leufkens HGM, Meij P, Hoekman J.

Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.

PMID:
29730080
32.

SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients.

Eektimmerman F, Swen JJ, Böhringer S, Aslibekyan S, Allaart CF, Guchelaar HJ.

Pharmacogenomics. 2018 May;19(7):613-619. doi: 10.2217/pgs-2018-0021. Epub 2018 Apr 27.

PMID:
29701127
33.

Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression.

Koudijs KKM, Terwisscha van Scheltinga AGT, Böhringer S, Schimmel KJM, Guchelaar HJ.

Sci Rep. 2018 Mar 27;8(1):5250. doi: 10.1038/s41598-018-23195-8.

34.

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.

Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CM, Burger DM, Moes DJAR.

Br J Clin Pharmacol. 2018 Jul;84(7):1575-1586. doi: 10.1111/bcp.13591. Epub 2018 May 6.

35.

EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.

de Wilde S, Coppens DGM, Hoekman J, de Bruin ML, Leufkens HGM, Guchelaar HJ, Meij P.

Drug Discov Today. 2018 Jul;23(7):1328-1333. doi: 10.1016/j.drudis.2018.03.008. Epub 2018 Mar 21. Review.

36.

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren A, Rodríguez-Antona C, García-Donas J, Böhringer S, Koudijs KKM, Kiemeney LALM, Rini BI, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2350-2356. doi: 10.1158/1078-0432.CCR-17-2815. Epub 2018 Feb 28.

37.

A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands.

Bank PC, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2018 Mar;19(4):311-319. doi: 10.2217/pgs-2017-0175. Epub 2018 Feb 23.

PMID:
29473451
38.

Pharmacogenetic Information in Clinical Guidelines: The European Perspective.

Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP).

Clin Pharmacol Ther. 2018 May;103(5):795-801. doi: 10.1002/cpt.1049. Epub 2018 Mar 30. Review.

PMID:
29460273
39.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19.

40.

Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project.

Blagec K, Koopmann R, Crommentuijn-van Rhenen M, Holsappel I, van der Wouden CH, Konta L, Xu H, Steinberger D, Just E, Swen JJ, Guchelaar HJ, Samwald M.

J Am Med Inform Assoc. 2018 Jul 1;25(7):893-898. doi: 10.1093/jamia/ocy005.

41.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

42.

The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome.

de Wilde S, de Jong MGH, Lipka AF, Guchelaar HJ, Schimmel KJM.

Eur J Pharm Sci. 2018 Mar 1;114:24-29. doi: 10.1016/j.ejps.2017.11.025. Epub 2017 Nov 28.

PMID:
29191521
43.

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.

Krens LL, Baas JM, Guchelaar HJ, Gelderblom H.

Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.

44.

Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Kievit W, Klungel OH, Verbeek ALM, Wong DR, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Bouvy ML, de Jong DJ.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):167-173. doi: 10.1097/MEG.0000000000001025.

45.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
46.

High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.

van der Stoep MYEC, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, Moes DJAR, Locatelli F, Guchelaar HJ, Zwaveling J, Lankester AC.

Br J Haematol. 2017 Dec;179(5):772-780. doi: 10.1111/bjh.14960. Epub 2017 Oct 19.

PMID:
29048102
47.

Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.

de Wilde S, de Jong MGH, Le Brun PPH, Guchelaar HJ, Schimmel KJM.

Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):3-8. doi: 10.1002/pds.4335. Epub 2017 Oct 19. Review.

PMID:
29047193
48.

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.

Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar HJ.

Clin Pharmacol Ther. 2018 Apr;103(4):599-618. doi: 10.1002/cpt.762. Epub 2017 Oct 10. Review.

49.

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ.

Aliment Pharmacol Ther. 2017 Nov;46(10):953-963. doi: 10.1111/apt.14323. Epub 2017 Sep 15.

50.

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.

Ketzer S, Schimmel K, Koopman M, Guchelaar HJ.

Clin Pharmacokinet. 2018 Apr;57(4):455-473. doi: 10.1007/s40262-017-0590-9. Review.

Supplemental Content

Loading ...
Support Center